IBC Legal is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Tuesday 4th December 2018
The Hotel,
Brussels, Belgium

Competition Law in the Pharmaceutical Sector

The 1-day essential review of the latest market trends, policy and case law developments - including invaluable practical strategies to address the new challenges currently affecting the pharmaceutical sector across Europe

Featuring the European Commission, national regulators, in-house counsel and eminent lawyers from across the industry

Why attend this highly focused, in-depth conference?

Hear from the Commission

Hear directly from Paul Csiszár, Director “Basic Industries, Manufacturing and Agriculture”, DG Competition, European Commission on how they are approaching the pharmaceutical sector. You will have an opportunity to pose your questions to Paul during the session. 

Excessive Pricing Cases

Review the Commission’s forthcoming decisions and UK appeal in excessive pricing cases. Join us to analyse how the different national competition authorities are approaching these cases and gain practical strategies to reduce your competition law risk.

Rebates and Discounts

This session will offer a review of recent decisions and an in-depth analysis of why discounts and rebates are problematic. Our speakers will also offer practical strategies to help you reduce risks. 

Reverse Patent Settlements

Gain a practical update on Lundbeck, Servier and UK Paroxetine cases. During this session you will have an opportunity to look over the pond and analyse what lessons can be learnt from US cases including the Actavis judgement.

National Developments

During this interactive panel session our speakers from across Europe will review current developments at national levels. Key jurisdictions represented will include UK, France, Denmark, Italy and the Netherlands. 

Biologics & Biosimilars

During this brand new session, our speakers will discuss what biologics and biosimilars are and what regulatory considerations they pose. We will analyse how the market should be defined, implications for mergers and remedies and what they mean for lifecycle management.

Supporting Sponsors

Knowledge Partner:

Media Partner